Literature DB >> 6437662

Recovery from mitomycin C-induced hemolytic uremic syndrome. A case report.

J Verwey, E Boven, J van der Meulen, H M Pinedo.   

Abstract

Mitomycin C (MMC) is a cytotoxic agent that may induce a hemolytic uremic syndrome (HUS) with severe renal insufficiency. Of all reported patients with terminal renal failure only two survived with chronic hemodialysis. A patient with advanced gastric cancer in complete remission, who developed MMC-induced HUS, is reported; hemodialysis was necessary because of oliguria. Hemolysis subsided, and after addition of captopril renal function recovered partially. The patient is alive 6 months after discontinuation of hemodialysis. Recently she developed brain metastases. Symptoms of hemolysis did not recur. The pathogenesis and treatment of HUS are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437662     DOI: 10.1002/1097-0142(19841215)54:12<2878::aid-cncr2820541211>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.

Authors:  J Verweij; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Mitomycin C-induced organ toxicity in Wistar rats: a study with special focus on the kidney.

Authors:  J Verweij; S Kerpel-Fronius; M Stuurman; A J van Triet; L van Hattum; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Recovery of renal function after long-term dialysis in hemolytic uremic syndrome.

Authors:  Kathrin Brunner; Mario G Bianchetti; Thomas J Neuhaus
Journal:  Pediatr Nephrol       Date:  2003-11-27       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.